Molecular Partners AG (LON:0QXX)

Market Cap	88.78M
Revenue (ttm)	1.95M
Net Income (ttm)	-52.09M
Shares Out	n/a
EPS (ttm)	-1.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,500
Average Volume	1,953
Open	2.960
Previous Close	2.835
Day's Range	2.900 - 2.960
52-Week Range	2.800 - 5.990
Beta	0.55
RSI	45.11
Earnings Date	Aug 5, 2025

About Molecular Partners AG

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (D...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2004
• Employees: 159
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QXX

Financial Performance

In 2024, Molecular Partners AG's revenue was 4.97 million, a decrease of -29.38% compared to the previous year's 7.04 million. Losses were -54.04 million, -12.81% less than in 2023.

Financial numbers in CHF